North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
|
|
- Aubrey Matthews
- 5 years ago
- Views:
Transcription
1 THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document Control Prepared by Approved by Dr Emma Brown + Changes informed to NMcL Issue date Review date September 2016 Version This version V2.3 ( ) Page 1 of 10
2 General principles THIS DOCUMENT IS Clinical Management Guideline for Initial Diagnosis, pre-treatment Evaluation & Staging All patients (including those who decline, or are considered clinically not suitable for active treatment) should be registered with the appropriate Lung cancer MDT in order to ensure accurate data capture and an opportunity for peer review In advance of any patient being discussed at the specialist Lung Cancer MDT, it is important to have taken steps earliest to establish i) a definitive diagnosis ii) an indication of clinical staging (see page 10) All patients should be referred or made aware earliest to the service Lung Clinical Nurse Specialist for assessment and ongoing specialist advice, education, support and co-ordination of care for both the patient and their relatives throughout the treatment pathway: this is in addition to any other specialist referrals that may also be clinically required depending on individual patient circumstances. Key Points* For all patients either undergoing investigation for, or with a suspected/confirmed diagnosis of lung cancer: The informed wishes of individual patient must direct any decision making with respect to treatment choices within this Clinical Management Plan. The 7th edition of the TNM classification of lung cancer should be used for staging purposes The IASLC** international nodal map should be used in the assessment and staging of lymph node disease MRI or CT scanning of the head should be considered For all patients with a confirmed diagnosis of lung cancer and being considered potentially suitable for radical treatment: A CT scan of the chest, lower neck and upper abdomen with intravenous contrast medium administration should be arranged early in the diagnostic pathway Positron Emission Tomography (PET)-CT scanning should be made available. PET positive mediastinal nodes should be evaluated by further mediastinal sampling The presence of isolated distant metastases/synchronous tumours should be confirmed by biopsy or further imaging Radical treatment should be offered without further mediastinal lymph node sampling if there is no significant uptake in normal sized mediastinal lymph nodes on PET-CT scanning,. The adequacy of diagnostic and staging samples should be considered in the context of selection of patients for targeted therapy. Where there is negligible additional risk to the patient, ensure biopsy samples are taken in adequate numbers and size. Trans-bronchial Needle Aspiration (TBNA) and Endo-bronchial Ultrasound/Endoscopic Ultrasound (EBUS/EUS)-guided TBNA should be used as an initial diagnostic and staging procedure according to findings on CT or PET-CT scans. Confirm negative results obtained by TBNA and EBUS/EUS-guided TBNA by mediastinoscopy and lymph node biopsy where clinically appropriate. *Source: British Thoracic Society Guidelines on the radical management of patients with lung cancer, Thorax, 2010;65 (Supp111) ** IASLC International Association for the Study of Lung Cancer V2.3 ( ) Page 2 of 10
3 Clinical Management Guideline for Radical Treatment - Stage I and II Disease THIS DOCUMENT IS Treatment and pathological stage Adjuvant Treatment Follow-up Initial Evaluation, Clinical Staging, Pre treatment & Evaluation; See (BTS Guideline) on Page 1 Surgical exploration and pt1 T2, N0 (Stage IA/B) pt1-2, NI (Stage IIA-B) pt1-2, N2-3 (Stage IIIA) Complete Incomplete Complete Incomplete Complete Incomplete Consider adjuvant SACT* Radiotherapy Adjuvant SACT* Adjuvant SACT* and radiotherapy Adjuvant SACT* Radiotherapy and SACT* Surveillance Unresectable Radical radiotherapy +/- SACT* For SACT (ie chemotherapy) regimens - see page 7/8 Refused to have surgery or medically inoperable Palliative Radiotherapy Radical Radiotherapy Chemo-radiotherapy Stereotatic Ablative Body Radiotherapy V2.3 ( ) Page 3 of 10
4 THIS DOCUMENT IS Clinical Management Guideline for Radical Treatment - Stage IIIA Disease Initial Evaluation Clinical Stage Pre-Treatment Evaluation Mediastinal Biopsy Initial and Adjuvant Treatment Unresectable/ Medically unfit Treat according to clinical stage Follow-up N2 Node Negative Assess for thoracotomy Surgical plus Mediastinal Lymph Node dissection N0-1 N2 Complete See Page 2 Adjuvant SACT* Refer to BTS Guideline (on Page 1) T1-3, N2 (Stage IIIA) PET Scan Mediastinal nodal sampling Assess medical Fitness N2 Node Positive PS 0 and single station disease Brain imaging PS 0 1 Multistation disease Brain imaging PS 2 Concurrent or sequential chemoradiotherapy* Radical radiotherapy CHART or 55/20 Incomplete Radiotherapy and SACT* Surveillance For SACT (ie chemotherapy) regimens - see page 7/8 Large volume of disease or Poor pulmonary function or Poor PS Palliative radiotherapy +/_ SACT Metastatic disease or pleural effusion See Stage IV Protocol (Page 6) V2.3 ( ) Page 4 of 10
5 THIS DOCUMENT IS Clinical Management Guideline for Radical Treatment - Stage IIIB Disease Initial Evaluation Clinical Stage Treatment Evaluation Primary Treatment Adjuvant Treatment Follow-up T1-3, N3 (Stage IIIB) Assess Volume of Disease & PS PS 0 or 1 PS2 Local symptoms Radical (chemo) radiotherapy* or SACT* +/- high dose palliative radiotherapy Palliative radiotherapy Consider SACT* Refer to BTS Guideline Page 1 Possibly resectable PS 0-1 Induction SACT* Surgical re-evaluation Surgery T4, N0 (Stage IIIB) No pleural effusion Unresectable PS 2 Radical (chemo) radiotherapy or SACT* +/- high dose palliative radiotherapy Radical Radiotherapy PS 0-1 Palliative radiotherapy for local symptoms Best Supportive Care Palliative Care Referral * For SACT (ie chemotherapy) regimens see page 7/8 Surveillance V2.3 ( ) Page 5 of 10
6 THIS DOCUMENT IS Clinical Management Guideline for Initial Treatment - Stage IV Disease Initial Evaluation Clinical Stage Pre-Treatment Evaluation Primary Treatment Adjuvant Treatment Stage IIIB T4 + Pleural or pericardial effusion Pleural or pericardial drainage Cytology negative Treatment according to T and N stage Refer to BTS Guideline Page 1 Cytology positive Local therapy if necessary (e g, pleurodesis, pericardial window) + treatment as for stage IV disease. (below) Stage IV or Malignant Pleural Effusion Performance Status Symptom Evaluation Tumour pathology assessment Palliative SACT* or biological therapy (page 6) Consider 2 nd /3 rd line systemic therapy Palliative Radiotherapy For SACT (ie chemotherapy) regimens - see page 7/8 Best Supportive Care Palliative Care Referral Consider Phase 1 / 2 trials V2.3 ( ) Page 6 of 10
7 Squamous Cell THIS DOCUMENT IS Clinical Management Guideline for Systemic Anti-Cancer Therapy Curative Intent Chemotherapy prior to surgical or sequential chemo-radiotherapy irrespective of EGFR Status Non- Squamous Cell Carboplatin + Gemcitabine Carboplatin [AUC* 5] IV infusion on Day 1 Gemcitabine 1250mg/m² IV infusion on Day(s) 1 & 8 Repeat every 3 weeks/21days Continue to maximum of 4 cycles Cisplatin + Docetaxel Cisplatin 75mg/m² IV infusion on Day 1 Docetaxel 75mg/m² IV infusion on Day 1 Repeat every 3 weeks Continue to a maximum of 4 cycles Concurrent Chemotherapy with radiotherapy [or SOCCAR] Cisplatin + Vinorelbine Cycles 1 (prior to commencement) & Cycle 4 (following after completion) of radiotherapy only Cisplatin 80mg/m² IV Infusion on Day 1 Vinorelbine 25mg/m² (50mg max) IV infusion on Day 1 Vinorelbine 60mg/m² (160mg max) Administered orally on Day 8 Cycle duration: 3 weeks/21days Cycles 2 & 3 (at the same time as receiving radiotherapy) Cisplatin 80mg/m 2 IV Infusion on Day(s) 1 & 8 Vinorelbine 15mg/m 2 IV Infusion on Day(s) 1 & 8 Cycle duration: 3 weeks/21days Cisplatin + Pemetrexed Cisplatin 75mg/m 2 IV infusion on Day 1 Pemetrexed 500mg/m 2 IV Infusion on Day 1 Repeat every 3 weeks Continue to maximum of 4 cycles Note: If Cisplatin contraindicated, replace with Carboplatin [AUC*5] Adjuvant Chemotherapy Cisplatin + Vinorelbine Cisplatin 80mg/m 2 IV Infusion on Day1 Vinorelbine 25mg/m 2 (50mg max) IV infusion on Day 1 Vinorelbine 60mg/m 2 (60mg max.) Administered orally on Day 8 Note: - If Cisplatin contraindicated, replace with Carboplatin [AUC*5] - Vinorelbine may be either IV infusion or Oral at the respective doses. *AUC Area under the Curve (as per Cockroft-Gault equation) SOCCAR - A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypo-fractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer V2.3 ( ) Page 7 of 10
8 Clinical Management Guideline for THIS DOCUMENT IS Patients newly diagnosed requiring palliative SACT At all stages in this flow chart consider patient performance status and participation in clinical trials. 1 st Line 2 nd Line 3 rd Line Adenocarcinoma EGFRm Erlotinib or Afatinib Cisplatin (or Carbo) Pemetrexed Docetaxel +/- nintedonib Adenocarcinoma EGFRw Non-squamous Cisplatin (or Carbo) & Pemetrexed Gemcitabine Docetaxol Progressive Disease on treatment If ALK-1 Translocation Give crizotinib Docetaxel +/- Nintedonib Trials or PAS Scheme Partial Response or Stable Disease on treatment Maintenance pemetrexed Progressive Disease Squamous, & not Otherwise specified Cisplatin (or Carbo) & Gemcitabine or Vinorelbine or Docetaxol Docetaxel No further chemotherapy Outside of trials EGFRm = Mutation EGFRw = Wild Type V2.3 ( ) Page 8 of 10
9 Clinical Management Guideline for Systemic Anti-Cancer Therapy Palliative Intent Afatinib Afatinib 40mg (escalating to 50mg if tolerated) Administered Orally Continue until disease progression or unacceptable toxicity. Carboplatin + Gemcitabine Carboplatin [AUC 5]* by IV infusion on Day 1 Gemcitabine 1250mg/m² by IV infusion on Days 1 & 8 Repeat every 3 weeks/21 days Continue to a maximum of 4 cycles Cisplatin + Pemetrexed Cisplatin 75mg/m² by IV infusion on Day 1 Pemetrexed 500mg/m² by IV infusion on Day 1 Repeat every 3 weeks/21 days Continueto a maximum for 4 cycles. Note: If Cisplatin contraindicated, replace with Carboplatin [AUC*5] Cisplatin + Vinorelbine Cisplatin 80mg/m² IV Infusion on Day 1 Vinorelbine 25mg/m² (max. 50mg) IV infusion on Day 1 Vinorelbine 60mg/m² (max. 160mg) orally on Day 8 Repeat every 3 weeks/21 days Continue to a maximum of? cycles. Note: If Cisplatin contraindicated, replace with Carboplatin [AUC*5] and Vinorelbine may be either IV infusion or Oral at the respective doses. Crizotinib Crizotinib 250mg Administered orally Continue until disease progression or unacceptable toxicity Docetaxel Docetaxel 60-75mg/m² IV infusion on Day 1 Repeat every 3 weeks/21 days Continue until disease progression or unacceptable toxicity. Docetaxel + Nintedanib Docetaxel 60-75mg/m² IV infusion on Day 1 Nintedanib 200mg Administered orally from Days 2 to 21 Repeat every 3 weeks/21days Continue until disease progression or unacceptable toxicity. Erlotinib Erlotinib 150mg Administered orally Continue until disease progression or unacceptable toxicity. Maintenance Pemetrexed 500mg/m² IV infusion on Day 1 Repeated every 3 weeks/21days Continue until disease progression or unacceptable toxicity *AUC Area under the Curve (as per Cockroft-Gault equation) V2.3 ( ) Page 9 of 10
10 Primary Tumour (T) Clinical Management Guideline for THIS DOCUMENT IS AJCC TNM Lung Cancer Staging 7 th Edition 2009 TX T0 Tis T1 T1a T1b T2 T2a T2b T3 T4 Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy There is no evidence of primary tumour Carcinoma in situ Tumour 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (for example, not in the main bronchus)¹ Tumour 2 cm or less in greatest dimension Tumour more than 2 cm but 3 cm or less in greatest dimension Tumour more than 3 cm but 7 cm or less or tumour with any of the following features (T2 tumours with these features are classified T2a if 5 cm or less): involves main bronchus, 2 cm or more distal to the carina; invades visceral pleura (PL1 or PL2); associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung Tumour more than 3 cm but 5 cm or less in greatest dimension Tumour more than 5 cm but 7 cm or less in greatest dimension Tumour more than 7 cm or one that directly invades any of the following: parietal pleural (PL3), chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 2 cm distal to the carina¹ but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe Tumour of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, separate tumour nodule(s) in a different ipsilateral lobe Distant Metastasis (M) M0 No distant metastasis M1 Distant metastasis M1a Separate tumour nodule(s) in a contralateral lobe, tumour with pleural nodules or malignant pleural (or pericardial) effusion² M1b Distant metastasis (in extrathoracic organs) Regional Lymph Nodes (N) NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastases N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s) Notes: ¹ The uncommon superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which may extend proximally to the main bronchus, is also classified as T1a. ² Most pleural (and pericardial) effusions with lung cancer are due to tumour. In a few patients, however, multiple cytopathologic examinations of pleural (pericardial) fluid are negative for tumour, and the fluid is nonbloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumour, the effusion should be excluded as a staging element and the patient should be classified as M0. V2.3 ( ) Page 10 of 10
Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationClinical Management Guideline for Small Cell Lung Cancer
Diagnosis and Staging: Key Points 1. Ensure a CT scan that is
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Mesothelioma
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma [Based on WOSCAN SCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document
More informationThe 8th Edition Lung Cancer Stage Classification
The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology
More informationAJCC-NCRA Education Needs Assessment Results
AJCC-NCRA Education Needs Assessment Results Donna M. Gress, RHIT, CTR Survey Tool 1 Survey Development, Delivery, Analysis THANKS to NCRA for the following work Developed survey with input from partners
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationB REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment
B REAST STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi c a b c d TUMOR SIZE:
More informationB REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment
B REAST STAGING FORM Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery (DCIS) (LCIS) (Paget s) mi a b c a b c d TUMOR SIZE: S TAGE
More informationGUIDELINES FOR CANCER IMAGING Lung Cancer
GUIDELINES FOR CANCER IMAGING Lung Cancer Greater Manchester and Cheshire Cancer Network Cancer Imaging Cross-Cutting Group April 2010 1 INTRODUCTION This document is intended as a ready reference for
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer
THIS DOCUMENT North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationLung 8/7/14. Collecting Cancer Data: Lung NAACCR Webinar Series. August 7, 2014
Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationNon small cell Lung Cancer
Non small cell Lung Cancer The 13th refresher course for residents in radiation oncology Jiraporn Setakornnukul, M.D. Radiation oncology division, Radiology department Siriraj Hospital, Mahidol University
More information6 th Reprint Handbook Pages AJCC 7 th Edition
6 th Reprint Handbook Pages AJCC 7 th Edition AJCC 7 th Edition Errata for 6 th Reprint Table 1 Handbook No Significant Staging Clarifications for 6 th Reprint AJCC 7 th Edition Errata for 6 th Reprint
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationCollaborative Stage. Site-Specific Instructions - LUNG
Slide 1 Collaborative Stage Site-Specific Instructions - LUNG In this presentation, we are going to review the AJCC Cancer Staging criteria for the lung primary site. Slide 2 Reading Assignments As each
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationHistopathology of NSCLC, IHC markers and ptnm classification
ESMO Preceptorship on Non-Small Cell Lung Cancer November 15 th & 16 th 2017 Singapore Histopathology of NSCLC, IHC markers and ptnm classification Prof Keith M Kerr Department of Pathology, Aberdeen University
More informationGROUP 1: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases. Including: Excluding:
GROUP 1: Including: Excluding: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases Solid pulmonary nodules 8mm diameter / 300mm3 volume and BROCK risk of malignancy
More informationWHITE PAPER - SRS for Non Small Cell Lung Cancer
WHITE PAPER - SRS for Non Small Cell Lung Cancer I. Introduction This white paper will focus on non-small cell lung carcinoma with sections one though six comprising a general review of lung cancer from
More informationSeventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer. Quick Reference Chart and Diagrams
CHEST Special Features Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer Quick Reference Chart and Diagrams Omar Lababede, MD ; Moulay Meziane, MD ; and Thomas Rice, MD, FCCP
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Malignant Melanoma
Nth of Scotland Cancer Netwk Clinical Management Guideline f Malignant Melanoma Based on WOSCAN CMG with further consultation within NOSCAN UNCONTROLLED WHEN PRINTED Prepared by Approved by Issue date
More informationCollecting Cancer Data: Lung
Collecting Cancer Data: Lung NAACCR 2011 2012 Webinar Series 2/2/2012 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this
More informationLung Cancer Staging: The Revised TNM Classification
Norwegian Society of Thoracic Imaging Oslo, October 2011 Lung Cancer Staging: The Revised TNM Classification Sujal R Desai King s College Hospital, London Lung Cancer The Scale of the Problem Leading cause
More informationLung /1/16. Please submit all questions concerning webinar content through the Q&A panel. Reminder:
1 NAACCR 2015-2016 Webinar Series Collecting Cancer Data: Lung NAACCR 2015 2016 Webinar Series Presented by: Angela Martin amartin@naaccr.org Jim Hofferkamp jhofferkamp@naaccr.org Q&A Please submit all
More informationLungStage. Bringing machine learning to Nuclear Medicine and Lung Cancer using Big Data, Machine Learning and Multicenter Studies
LungStage Bringing machine learning to Nuclear Medicine and Lung Cancer using Big Data, Machine Learning and Multicenter Studies Medical Team: Bram Stieltjes, MD PhD; Alex Sauter, MD; Gregor Sommer, MD;
More informationLUNG STAGING FORM LATERALITY: LEFT RIGHT BILATERAL
LUNG STAGING FORM LATERALITY: LEFT RIGHT BILATERAL ( ) Tx Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Oropharyngeal Cancer
Nth of Scotland Cancer Netwk Clinical Management Guideline f Oropharyngeal Cancer UNCONTROLLED WHEN PRINTED Based on NHST CMG with further extensive consultation within NOSCAN DOCUMENT CONTROL Original
More informationCase Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer. Doug Rahn 6/1/12
Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer Doug Rahn 6/1/12 Outline I. Presentation of Case II. Epidemiology III. Staging IV. Review of Literature V. Recommendations VI.
More informationLung cancer LUNG CANCER. Box 1 Clinical signs
22 LUNG CANCER Lung cancer Bronchial carcinoma refers to two distinct clinical entities small cell and non-small cell carcinoma. Although these conditions have much in common, with broadly similar presenting
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary
North of Scotland Cancer Network Cancer of the Ovary Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by NOSCAN Gynaecology Cancer
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationREGIONAL LUNG CANCER GROUP
REGIONAL LUNG CANCER GROUP Document Title Guidelines for the Management of Lung Cancer (Non Small Cell Lung Cancer, Small Cell Lung Cancer and Mesothelioma) Document Date Document Purpose January 2010
More informationFDG PET/CT in Lung Cancer Read with the experts. Homer A. Macapinlac, M.D.
FDG PET/CT in Lung Cancer Read with the experts Homer A. Macapinlac, M.D. Patient with suspected lung cancer presents with left sided chest pain T3 What is the T stage of this patient? A) T2a B) T2b C)
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationImaging of Lung Cancer: A Review of the 8 th TNM Staging System
Imaging of Lung Cancer: A Review of the 8 th TNM Staging System Travis S Henry, MD Associate Professor of Clinical Radiology Cardiac and Pulmonary Imaging Section University of California, San Francisco
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More information8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC
8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour
More informationLung Cancer Case Study
Lung Cancer Case Study Presented by s GP Education Programme 2 Part One Initial presentation 60 year old lady, presents with a 6 week history of right sided chest pain. The pain is like a dull ache, but
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO)
North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO) UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Original Prepared by NMcL April 2016
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationTumor Board Discussions: Case 1
Tumor Board Discussions: Case 1 David S. Ettinger, MD The Alex Grass Professor of Oncology Johns Hopkins University School of Medicine Baltimore, Maryland Case #1 50-year-old Asian female, never smoker
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationMediastinal Mysteries: What can be solved with EBUS?
Mediastinal Mysteries: What can be solved with EBUS? W. Graham Carlos MD Pulmonary & Critical Care Fellow Indiana University School of Medicine Disclosures None Objectives Introduce you to the technique
More informationLung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
More informationAudit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: May 2016
NORTH OF SCOTLAND PLANNING GROUP Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed April 2014 March 2015 Published: May 2016 Mr Hardy Remmen
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationAudit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017
Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed January December 2016 Published: November 2017 Hardy Remmen NOSCAN Lung Cancer MCN Clinical
More informationLung and Aerodigestive malignancies
Lung and Aerodigestive malignancies Nabil F Saba MD, FACP Professor, Director of the Head and Neck Oncology Program, Winship Cancer Institute Emory University COI I am a consultant for GSK, Merck, BMS,
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationACRIN NLST 6654 Primary Lung Cancer. F1/F2 Interval: to (mm-dd-yyyy) 1. Date of diagnosis: (mm-dd-yyyy)
No. F1/F2 Interval: - - 20 to - - 20 (mm-dd-yyyy) 1. Date of diagnosis: - - 20 (mm-dd-yyyy) 2. Samples recorded: ZP Number S-Number 1) 2) 3) 4) (Refer to Form PX, Column 1. In the rare instance of a diagnosis
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More information6 th Reprint Manual Pages AJCC 7 th Edition
6 th Reprint Manual Pages AJCC 7 th Edition AJCC 7 th Edition Errata for 6 th Reprint Table 1 Manual No Significant Staging Clarifications for 6 th Reprint AJCC 7 th Edition Errata for 6 th Reprint Table
More informationEarly and locally advanced non-small-cell lung cancer (NSCLC)
Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationLYMPHATIC DRAINAGE IN THE HEAD & NECK
LYMPHATIC DRAINAGE IN THE HEAD & NECK Like other parts of the body, the head and neck contains lymph nodes (commonly called glands). Which form part of the overall Lymphatic Drainage system of the body.
More informationSingle Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
More informationCase Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationThe 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
More informationLung cancer. The diagnosis and treatment of lung cancer. Issued: April NICE clinical guideline 121. guidance.nice.org.
Lung cancer The diagnosis and treatment of lung cancer Issued: April 2011 NICE clinical guideline 121 guidance.nice.org.uk/cg121 NICE has accredited the process used by the Centre for Clinical Practice
More informationLung Carcinoid Tumor Early Detection, Diagnosis, and Staging
Lung Carcinoid Tumor Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can
More informationRadiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh
Radiological staging of lung cancer Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh Bronchogenic Carcinoma Accounts for 14% of new cancer diagnoses in 2012. Estimated to kill ~150,000
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationThe International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements
Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 6 1.5. Primary Tumour Description... 10 1.6.
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationGuideline for the Management of Vulval Cancer
Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationLung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the highest incidence
LUNG CANCER 2010 Mark B. Stoopler, M.D. Division of Medical Oncology Lung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationLung Cancer Clinical Data Standards
For reference only Do Not Use For more information, contact; cdsis@nhs.net Lung Cancer Clinical Data Standards June 2008 National Clinical Dataset Development Programme (NCDDP) Support Team Information
More informationNeues von der IASLC - Proposals zur 8ten Edition der TNM Klassifikation für das Lungenkarzinom. J. Pfannschmidt
Neues von der IASLC - Proposals zur 8ten Edition der TNM Klassifikation für das Lungenkarzinom J. Pfannschmidt Immunhistochemie durchgängig zur Klassifizierung Integration der molekularen Analyse Neuklassifizierung
More informationFor personal use only. Not to be reproduced without permission of the editor
For personal use only. Not to be reproduced without permission of the editor (permissions@pharmj.org.uk) An overview of lung cancer November is Lung Cancer Awareness Month. With public smoking bans springing
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationManagement of Lung Cancer in Older Adults
Management of Lung Cancer in Older Adults Arti Hurria, MD; Mark G. Kris, MD ABSTRACT Lung cancer is the leading cause of cancer death in the United States. At the time of diagnosis, most patients are older
More information3/30/2009 Lung Cancer Deaths 2008 Lung Cancer Deaths Lung Cancer Deaths--Males Males 5
LUNG CANCER 2009 Mark B. Stoopler, M.D. Division of Medical Oncology Very common Very lethal Lung Cancer Median age of diagnosis approximately 70 years, but affects all ages(even pediatric!) Advances in
More informationImpact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer
Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram
More informationLung Cancer Incidence 2008 Lung Cancer Deaths-Males 2008 Incidence Total U.S.(all types): 1,437,180 Lung Cancer Deaths-Females Lung cancer 215,000(15%
Multidisciplinary approach 2009 Mark B. Stoopler, M.D. Division of Medical Oncology Neurology Neurosurgery Orthopedic surgery General surgery Vascular surgery Gastroenterology Cardiology Lung Cancer Very
More informationSpecial Treatment Issues in Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Special Treatment Issues in Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationStaging of lung cancer provides a common language
The 1997 International Staging System for Non-Small Cell Lung Cancer* Have All the Issues Been Addressed? Swan S. Leong, MD; Caio M. Rocha Lima, MD; Carol A. Sherman, MD; and Mark R. Green, MD The International
More informationLung Cancer. Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology
Lung Cancer Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology ABOUT ASCO The American Society of Clinical Oncology (ASCO) is the world s leading professional organization
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationTumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma
Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given
More informationTable 1 Major Classifications of Lung Cancer. Non Small Cell Lung Cancer Adenocarcinoma
VIII LUNG CANCER Jeffrey Crawford, m.d. Definition and Classifications Bronchogenic carcinoma of the lung lung cancer comprises a group of malignant neoplasms that arise from bronchial epithelium. The
More information